QuarterHawk — Equity ResearchQuarterHawk — Equity Research

CorMedix Inc. (CRMD)

Healthcare

Actionable
Fundamental
4
Sentiment
3
Technical
3

Momentum breakout buy-stop: 7.46 (GTC) triggers above the settled 10-09 high 7.455 out of the five-session 7.06-7.455 base; protective stop 7.13 below the 7.18 swing low (risk 0.33 = 1.32xATR, clears the 0.5xATR floor); targets 7.96 / 8.34; R/R 1.52. All gates pass - price under $25, liquidity above floor (20-day approx. $6.81M), no dividend, and confirmed earnings 2026-11-11 sits outside both the +/-3-day blackout and the 15-day holding window (horizon 2026-10-30); max overnight gap 0.14%.

Analysis as of 2026-10-09· more than 2 trading days ago

Company overview

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing treatments for infectious and inflammatory conditions. Its primary product, DefenCath/Neutrolin, is designed to prevent catheter-related infections and blood clots in patients using central venous catheters. The company operates in the U.S. and internationally, with headquarters in Berkeley Heights, New Jersey.

Fundamental

good
Fundamental4
Strong fundamentals

CorMedix shows strong profitability and liquidity, but faces reimbursement and integration risks.

CorMedix is no longer a pre-revenue biotech: recent SEC filings show a profitable commercial anti-infectives business (DefenCath plus the Melinta portfolio) with strong liquidity and cash generation. Current multiples are very low (P/E ~3.4, EV/EBITDA ~2.1) and balance-sheet risk looks manageable, but investors are being asked to underwrite reimbursement-policy risk (TDAPA step-down beginning July 2026), acquisition integration, and remediation of a material internal-control weakness; discounted-cash-flow outputs also point to downside, so this is attractive but not low-risk.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is cooling post-earnings, with cautious headlines and a thin forward calendar.

A market-rewarded Q2 print (revenue $101.9M, FY26 adjusted-EBITDA guidance raised to $125–140M, analyzer score +0.6) is digesting into a positive-but-cooling tape (in-window aggregate ≈ +0.18, price fading from $8.43 to ~$7.96), with the next named driver an expected REZZAYO sNDA filing (announced, date TBD) and the post-TDAPA reimbursement transition still under watch. The sentiment delta is determinate at item level — flat-to-cooling within positive territory (baseline aggregate under-sampled at one scored item) — retail is indeterminate, and the Red-Flag Screen is clean, leaving a mixed/forming setup driven by a trailing, partially-priced catalyst set.

Technical

fair
Technical3
Breakout pending

The chart shows a constructive base with improving momentum, setting up for a potential breakout.

Mixed chart (score 3): short-term internals are constructive - no lower close in five consecutive sessions off the 7.06 low (7.19 to 7.38), higher lows (7.13 to 7.25), MACD histogram improving four straight sessions (-0.06 to -0.03), RSI recovering from 31.5 to 39.25, price back above DEMA14/TEMA14/WMA9 (7.29/7.23/7.34) and daily VWAP (7.36), and Friday's close (7.38, +0.82%) on 1.3x average volume - while the medium-term frame remains bearish (price below SMA20/50/200 and EMA9/EMA21; MACD line negative at -0.19; ADX 16.7 = no strong trend). The constructive turn against a defined 7.455 base top makes the breakout-pending stop entry the qualifying setup; the pullback/oversold limit alternative is countertrend (price < SMA50 with MACD < 0; also below a declining SMA200 without a reclaim) and is rejected. All hard gates pass; R/R 1.52.

You’re looking at 2026-10-09 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.